Rize Oncology (XCNQ:RIZE) ROE % Adjusted to Book Value : -112.91% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology ROE % Adjusted to Book Value?

Rize Oncology's ROE % for the quarter that ended in Sep. 2024 was -49.68%. Rize Oncology's PB Ratio for the quarter that ended in Sep. 2024 was 0.44. Rize Oncology's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -112.91%.

Rize Oncology ROE % Adjusted to Book Value Historical Data

The historical data trend for Rize Oncology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rize Oncology ROE % Adjusted to Book Value Chart

Rize Oncology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

-89.10

-50.96

Rize Oncology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial											-8.52	-108.52	-63.42	-28.89	-112.91

Competitive Comparison of Rize Oncology's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Rize Oncology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rize Oncology's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rize Oncology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Rize Oncology's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Rize Oncology ROE % Adjusted to Book Value Calculation

Rize Oncology's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-42.30%	/	0.83
	=	-50.96%

Rize Oncology's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-49.68%	/	0.44
	=	-112.91%

Rize Oncology ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Rize Oncology's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Rize Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, X1X 1X1

Website

https://www.rizeoncology.com

Rize Oncology Inc is is a pharmaceutical company. The company is engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecule targeting soft tissue sarcoma and other cancers.

Executives

William James Garner

10% Security Holder, Director

Rize Oncology Headlines

No Headlines